Detalle Publicación

ARTÍCULO
Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM
Autores: Mateos, M. V.; Martínez-López, J.; Hernandez, M. T.; Ocio, E. M.; Rosiñol, L.; Martínez, R.; Teruel, A. I. ; Gutierrez, N. C.; Ramos, M. L. M.; Oriol, A.; Bargay, J.; Bengoechea, E.; Gonzalez, Y.; Perez de Oteyza, J.; Gironella, M.; Encinas, C.; Martin, J.; Cabrera, C.; Paiva, Bruno; Cedena, M. T.; Puig, N.; Bladè, J.; Lahuerta, J. J.; San Miguel Izquierdo, Jesús
Título de la revista: BLOOD
ISSN: 0006-4971
Volumen: 127
Número: 4
Páginas: 420 - 425
Fecha de publicación: 2016
Resumen:
Bortezomib plus melphalan and prednisone (VMP) and lenalidomide plus low-dose dexamethasone (Rd) are 2 standards of care for elderly untreated multiple myeloma (MM) patients. We planned to use VMP and Rd for 18 cycles in a sequential or alternating scheme. Patients (233) with untreated MM, >65 years, were randomized to receive 9 cycles of VMP followed by 9 cycles of Rd (sequential scheme; n = 118) vs 1 cycle of VMP followed by 1 cycle of Rd, and so on, up to 18 cycles (alternating scheme; n 5115). VMP consisted of one 6-week cycle of bortezomib using a biweekly schedule, followed by eight 5-week cycles of once-weekly VMP. Rd included nine 4-week cycles of Rd. The primary end points were 18-month progression free survival (PFS) and safety profile of both schemes. The 18-month PFS was 74% and 80% in the sequential and alternating arms, respectively (P = .21). The sequential and alternating groups exhibited similar hematologic and non-hematologic toxicity. Both arms yielded similar complete response rate (42% and 40%), median PFS (32 months vs 34 months, P 5.65), and 3-year overall survival (72% vs 74%, P 5.63). The benefit of both schemes was remarkable in patients aged 65 to 75 years. In addition, achieving complete and immunophenotypic response was associated with better outcome. The present approach, based on VMP and Rd, is associated with high efficacy and acceptable toxicity profile with no differences between the sequential and alternating regimens. This trial was registered at www.clinicaltrials.gov as #NCT00443235.